Aktieanalys

Optomed Q4: Lower sales than anticipated, but a major catalyst is getting closer - Redeye

Redeye Publicerad: 16 Feb 07:35

Redeye provides an update in relation to Optomed’s Q4 2023 report. The sales of EUR3.7m during the quarter were lower than anticipated. However, we learned that the additional data has been submitted to the FDA and that Optomed is one step closer to a potential approval. Based on the report, we have made some changes in our short-term estimates; however, the changes do not render an updated fair value range, including a base case of EUR7.5.

Länk till analysen i sin helhet: https://www.redeye.se/research/980095/optomed-q4-lower-sales-than-anticipated-but-a-major-catalyst-is-getting-closer?utm_source=finwire&utm_medium=RSS

Nyheter om Optomed

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!